Larkspur Biosciences to Present New Preclinical Research on Lead Development Program Candidate, a First-in-Class PIP4K2C Protein Degrader, at AACR 2024
28 mars 2024 08h00 HE
|
Larkspur Biosciences, Inc.
Larkspur Biosciences to Present New Preclinical Research on Lead Development Program Candidate, a First-in-Class PIP4K2C Protein Degrader, at AACR 2024
Unnatural Products, Inc. Enters Research Collaboration with Merck
23 janv. 2024 09h00 HE
|
Unnatural Products
Santa Cruz, Calif., Jan. 23, 2024 (GLOBE NEWSWIRE) -- Unnatural Products, Inc. (UNP), a biotech company pairing AI with chemistry to enable the next generation of molecularly targeted therapeutics,...
Veru Inc.’s Oncology Drug Research Program Partner, The University of Tennessee Health Science Center, Awarded Two New Federal Grants
21 juin 2023 08h30 HE
|
Veru Inc.
Research grants from U.S. Department of Defense (DoD) and National Cancer Institute’s Research Project Grant (NCI R01) awarded to UTHSC to study new types of targeting agents for multiple cancer...
NuProbe BDA Technology Enables Highly Sensitive Detection of Low-Level Variants for Oncology Research
03 mai 2023 10h00 HE
|
NuProbe USA Inc
Houston, May 03, 2023 (GLOBE NEWSWIRE) -- NuProbe, a genomics company developing ultrasensitive research assays for detecting and monitoring low-frequency mutations, gene fusions, and copy number...
Zai Lab to Present Two New Phase 3 Analyses for Niraparib in Ovarian Cancer at the 2023 ESMO Gynaecological Cancers Congress
22 févr. 2023 16h30 HE
|
Zai Lab Limited
SHANGHAI, China and CAMBRIDGE, Mass., Feb. 22, 2023 (GLOBE NEWSWIRE) -- Zai Lab Limited (NASDAQ: ZLAB; HKEX: 9688) will present two oral presentations highlighting the ad hoc interim overall...
Bio-Rad and NuProbe Enter into an Exclusive Licensing Agreement for Digital PCR Applications
07 nov. 2022 14h32 HE
|
NuProbe USA Inc
Hercules, Calif. and Houston, Texas, Nov. 07, 2022 (GLOBE NEWSWIRE) -- Bio-Rad Laboratories, Inc. (NYSE: BIO and BIOb), a global leader in life science research and clinical diagnostic products, and...
3-Year Global MPN Interferon Initiative Report Released by MPN Research Foundation
01 nov. 2021 08h45 HE
|
MPN Research Foundation
Chicago, IL, Nov. 01, 2021 (GLOBE NEWSWIRE) -- In real-world usage and in clinical trials, interferon (IFN) in a variety of forms has shown high rates of hematologic and molecular responses in many...
American Oncology Network & Sarah Cannon Research Institute Expand Cancer Research Collaboration with Addition of Genesis Cancer and Blood Institute
22 sept. 2021 08h00 HE
|
American Oncology Network
Fort Myers, Fla. & Nashville, Tenn., Sept. 22, 2021 (GLOBE NEWSWIRE) -- American Oncology Network, LLC (AON) and Sarah Cannon Research Institute announced today the addition of AON partner...
Cybrexa Therapeutics Expands Scientific Advisory Board With Appointment of Leader in Lung Cancer Research Roy Herbst, M.D., Ph.D.
03 août 2020 07h00 HE
|
Cybrexa Therapeutics
NEW HAVEN, Conn., Aug. 03, 2020 (GLOBE NEWSWIRE) -- Cybrexa Therapeutics, an oncology-focused biotechnology company developing a new class of therapeutics through its alphalex™ tumor targeting...
Rubius Therapeutics Highlights Preclinical Data for RTX-321, a Red Cell Therapeutic™ Oncology Product Candidate for HPV-Positive Cancers, at the American Association of Cancer Research Virtual Annual Meeting II
22 juin 2020 08h00 HE
|
Rubius Therapeutics
CAMBRIDGE, Mass., June 22, 2020 (GLOBE NEWSWIRE) -- Rubius Therapeutics, Inc. (Nasdaq: RUBY), a clinical-stage biopharmaceutical company that is genetically engineering red blood cells to create an...